Efficacy and Safety of Recombinant Human Interferon α-1b in the Treatment of Rotavirus Enteritis in Children
Objective:To observe the efficacy and safety of Recombinant Human Interferon α-1b in the treatment of rotavirus enteritis in children.Method:A total of 186 children with rotavirus infected enteritis admitted to Zhijiang People's Hospital from June 2022 to June 2023 were selected and divided into control group and observation group according to random number table method,with 93 cases in each group.The control group was treated with clinical routine treatment and Saccharomyces Boulardii Sachets,and the observation group was treated with Recombinant Human Interferon α-1b on the basis of the control group,both group treated for 3 d.The clinical efficacy after 3 d of treatment,the remission of clinical symptoms,the indexes of intestinal mucosal damage,intestinal flora,immune function before and after 3 d of treatment,and the safety during the study were compared between the two groups.Result:After 3 d of treatment,the total effective rate of observation group was higher than that of control group;the time of abdominal pain disappearance,diarrhea prevention and heat regression in the observation group were earlier than those in the control group;after 3 d of treatment,the colony number of Lactobacillus,Bifidobacterium and Escherichia coli in both groups were higher than those before treatment,and the colony number in the observation group were higher than those in the control group,while the Enterococcus faecalis colony number in both groups were lower than those before treatment,and the observation group was lower than the control group;after 3 d of treatment,serum levels of serum advanced glycation end products(AGEs),endotoxin(ET),diamine oxidase(DAO)in both groups were decreased compared with before treatment,and the levels in the observation group were lower than those in the control group.After 3 d of treatment,peripheral blood CD4+and CD4+/CD8+increased in both groups compared with before treatment,the levels in the observation group were higher than those in the control group,peripheral blood CD8+was lower than before treatment,the observation group was lower than the control group;the incidence of adverse reactions in the observation group was lower than that in the control group;compared with the above indexes,the differences were statistically significant(P<0.05).Conclusion:In the clinical treatment of rotavirus infected enteritis in children,the application of Recombinant Human Interferon α-1b can obviously improve the clinical symptoms of children,improve intestinal flora,enhance immunity,and relieve intestinal mucosal injury,with high safety and remarkable curative effect.
RotavirusInfectious enteritisChildrenRecombinant Human Interferon α-1bSaccharomyces Boulardii Sachets
国家科技期刊平台
NSTL
万方数据
